20993 ⎘
Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Hormones Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
Long-Acting Formulations of Insulin
#2Vasoactive lntestinal Peptide Release From Microparticles
#3MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF
#4PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1-AGONIST AND METHIONINE
#5METHODS AND COMPOSITIONS FOR TREATING MUSCLE DISEASE AND DISORDERS
#6MODIFIED VASOACTIVE INTESTINAL PEPTIDES
#7PHARMACEUTICAL COMPOSITIONS AND METHODS
#8TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA WITH GLP-1 ANTAGONIST EXENDIN(9-39)
#9Formulations of Terlipressin
#10METHOD FOR IMPROVING AUDITORY PERCEPTION USING A VIPR1 INHIBITOR
#11TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA WITH EXENDIN (9-39)
#12METHODS AND COMPOSITIONS FOR INDUCING DIFFERENTIATION OF HUMAN BROWN ADIPOCYTE PROGENITORS
#13HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME
#14COMPOSITION FOR ORALLY ADMINISTERED FORMULATION CONTAINING GLP-1 ANALOGUE
#15Compositions and Methods for the Prevention and Treatment of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior
#16NF-KB AS BIOMARKER FOR ASSESSING TREATMENT EFFICACY IN PARKINSON'S DISEASE
#17MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF
#18USE OF AVIPTADIL ALONE OR IN COMBINATION WITH ALPHA LIPOIC ACID AS A THERAPEUTIC MEDICAMENT FOR POST-VIRAL INFECTION SYNDROME
#19POEGMA COPOLYMER CONJUGATES AND METHODS OF TREATING DISEASES
#20PAC1 ANTIBODIES AND USES THEREOF
#21MODIFIED VASOACTIVE INTESTINAL PEPTIDES
#22Treatment of post-bariatric hypoglycemia with exendin (9-39)
#23NEW DOSAGE REGIMEN FOR INHALED VASOACTIVE INTESTINAL POLYPEPTIDE
#24Treatment of hyperinsulinemic hypoglycemia with GLP-1 antagonist exendin(9-39)
#25METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES
#26Antagonism of the VIP Signaling Pathway
#27Methods of reducing severity of glaucoma by intravitreal administration of insulin-like growth factor binding protein-like 1 (IGFBPL1)
#28Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer, infections and autoimmune disorders
#29VASOACTIVE INTESTINAL PEPTIDE FUSION PROTEINS FOR THE TREATMENT OF COVID-19
#30HUMAN ANTI-INFLAMMATORY PEPTIDES FOR THE INHALATORY TREATMENT OF INFLAMMATORY PULMONARY ISSUES
#31PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME
#32Pharmaceutical composition comprising a GLP-1-agonist and methionine
#33IMPLANTABLE MEDICAL DEVICES FOR EXTENDED RELEASE OF THERAPEUTIC AGENTS
#34THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES
#35ORALLY DELIVERED THERAPEUTICAL COMPOSITION AND USE THEREOF
#36METHODS AND COMPOSITIONS FOR INDUCING DIFFERENTIATION OF HUMAN BROWN ADIPOCYTE PROGENITORS
#37METHODS AND COMPOSITIONS FOR TREATING MUSCLE DISEASE AND DISORDERS
#38PAC1 receptor agonists (MAXCAPs) and uses thereof
#39Formulations of terlipressin
#40Formulations of Terlipressin
#41VASOACTIVE INTESTINAL PEPTIDE (VIP) FOR USE IN THE TREATMENT OF DRUG-INDUCED PNEUMONITIS
#42Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and methods of making thereof
#43Dosage regimen for inhaled vasoactive intestinal polypeptide
#44Glucagon derivative and a composition comprising a long acting conjugate of the same
#45Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating
#46METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS
#47Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
#48Vasoactive lntestinal Peptide Release From Microparticles
#49Treatment of post-bariatric hypoglycemia with exendin (9-39)
#50Long-Acting Formulations of Insulin
#51Treatment of post-bariatric hypoglycemia with GLP-1 antagonists
#52Compositions for Controlling Neuronal Outgrowth
#53HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME
#54Stimuli-responsive PEG-like polymer-based drug delivery platform
#55Methods and compositions for oral administration of proteins
#56Methods and compositions for treating muscle disease and disorders
#57PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1-AGONIST AND METHIONINE
#58Vasointestinal peptide receptor inhibitors for enhancement of gastrointestinal health
#59Methods for treating a headache condition using anti-human PAC1 antibodies or antigen-binding fragments thereof
#60SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS CARRIERS
#61CONTROLLED RELEASE FORMULATIONS FOR THE INDUCTION AND PROLIFERATION OF BLOOD CELLS
#62POLYMER-BASED SUSTAINED RELEASE DEVICE
#63Long-Acting Formulations of Insulin
#64Peptides comprising non-natural amino acids and methods of making and using the same
#65Implantable medical devices for extended release of therapeutic agents
#66Therapeutic agents comprising a BMP-9 peptide and eleastin-like peptides
#67Treatment of post-bariatric hypoglycemia with GLP-1 antagonists
#68Treatment of post-bariatric hypoglycemia with exendin (9-39)
#69Glucagon derivative and a composition comprising a long acting conjugate of the same
#70Long-Acting Formulations of Insulin
#71METHODS AND COMPOSITIONS FOR REDUCING CORNEAL ENDOTHELIAL CELL LOSS
#72Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders
#73OIL BASED FORMULATIONS FOR SUBLINGUAL AND BUCCAL DELIVERY
#74Long-Acting Formulations of Insulin
#75PAC1 receptor agonists (MAXCAPS) and uses thereof
#76Delivery Scaffolds and Related Methods of Use
#77PAC1 antibodies and uses thereof
#78Pharmaceutical Composition Comprising a GLP-1-Agonist and Methionine
#79Multi-factor hair growth formulation
#80POLYMER-BASED SUSTAINED RELEASE DEVICE
#81Biomarkers for monitoring immune transformation
#82Methods of increasing nutrient absorption in the intestine using therapeutic agents comprising GLP-2 and elastin-like peptides
#83Pharmaceutical Composition for Use in the Treatment of a Neurodegenerative Disease
#84GLYCOPEPTIDES AND USES THEREOF
#85Long-Acting Formulations of Insulin
#86Implantable drug delivery device
#87Methods and compositions for oral administration of proteins
#88PROTEIN CONJUGATE USING A FATTY ACID DERIVATIVE AND METHOD FOR PREPARATION THEREOF
#89Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
#90Methods and compositions for treating muscle disease and disorders
#91Implantable medical devices for extended release of therapeutic agents
#92A PROTEIN CONJUGATE COMPRISING MULTIPLE PHYSIOLOGICALLY ACTIVE POLYPEPTIDES AND AN IMMUNOGLOBULIN FC REGION
#93SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS CARRIERS
#94Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating
#95Devices, formulations, and methods for delivery of multiple beneficial agents
#96METHODS OF REDUCING CORNEAL ENDOTHELIAL CELL LOSS
#97Peptides comprising non-natural amino acids and methods of making and using the same
#98Highly active polypeptides and methods of making and using the same
#99Glucagon derivative and a composition comprising a long acting conjugate of the same
#100Compounds as peptidic GLP1/glucagon/GIP receptor agonists
#101Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists
#102Treatment of hyperinsulinemic hypoglycemia with GLP-1 antagonist exendin(9-39)
#103Treatment of hyperinsulinemic hypoglycemia with exendin (9-39)
#104Capsules with intracapsular microspheres for improved survival and function of encapsulated cells
#105SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND USES THEREOF
#106MODIFIED VASOACTIVE INTESTINAL PEPTIDES
#107Pharmaceutical composition comprising a GLP-1-agonist and methionine
#108Antagonism of the VIP signaling pathway
#109Exendin-4 analogue pegylated with polyethylene glycol or derivative thereof, preparation method thereof, and pharmaceutical composition for preventing or treating diabetes, containing same as active ingredient
#110Methods and compositions for treating cystic fibrosis
#111Combination therapy
#112Method for administering a sustained release formulation
#113TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF
#114Use of modified vasoactive intestinal peptides in the treatment of hypertension
#115NOVEL FORMULATIONS AND METHODS
#116Implantable drug delivery device
#117MODIFICATION OF FEEDING BEHAVIOR
#118Methods and compositions for inducing differentiation of human brown adipocyte progenitors
#119Nanoencapsulation of hydrophilic active compounds
#120Pharmaceutical composition for use in the treatment of a neurodegenerative disease
#121Novel Glucagon Analogues
#122SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS CARRIERS
#123Mounting arrangement and coupling assembly for a drug-delivery device
#124Mounting arrangement and coupling assembly for a drug-delivery device
#125Reversible pegylated drugs
#126Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
#127METHODS OF REDUCING CORNEAL ENDOTHELIAL CELL LOSS
#128PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF
#129STABLE AQUEOUS PARENTERAL PHARMACEUTICAL COMPOSITIONS OF INSULINOTROPIC PEPTIDES
#130Long-Acting Formulations of Insulin
#131VIP fragments and methods of use
#132Modified vasoactive intestinal peptides
#133Implantable medical devices for extended release of therapeutic agents
#134Glycosylated PACAP/VIP analogues with enhanced CNS penetration for treatment of neurodegenerative diseases
#135Peptides comprising non-natural amino acids and methods of making and using the same
#136Combination therapy
#137Therapeutic agents comprising a GLP-2 peptide and elastin-like peptides
#138Use of PACAP for the treatment of viral infections in aquatic organisms
#139Treatment of neurological diseases
#140Manipulation of hairy and enhancer of split 3 (Hes3) and its regulators/mediators as an anti-cancer strategy
#141Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
#142FORMULATIONS OF ACTIVE AGENTS FOR SUSTAINED RELEASE
#143Drug delivery device with drug container comprising a sensor and optical data transmission system
#144Pharmaceutical microparticulate compositions of polypeptides
#145Long-Acting Formulations of Insulin
#146Methods of managing graft versus host disease
#147TRANSMUCOSAL DELIVERY OF PEPTIDES AND PROTEINS
#148Methods and compositions for inhibiting diseases of the central nervous system
#149TRANSMUCOSAL DELIVERY OF ENGINEERED POLYPEPTIDES
#150Use of modified vasoactive intestinal peptides in the treatment of hypertension
#151Devices, formulations, and methods for delivery of multiple beneficial agents
#152ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE
#153Therapeutic agents comprising fusions of growth hormone and elastic peptides
#154Controlled release formulations for the induction and proliferation of blood cells
#155GLP-1, exendin-4, peptide analogs and uses thereof
#156VIP fragments and methods of use
#157Compositions and methods for the treatment of retinal degeneration
#158Orally administered plastid expressed cholera toxin B subunit-exendin 4 as treatment for type 2 diabetes
#159NOVEL FORMULATIONS AND METHODS
#160OPHTHALMIC PREPARATIONS BASED ON PACAP (PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE) WHICH RESTORE THE NORMAL VISUAL FUNCTION IN EARLY GLAUCOMA
#161Use of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP analogs for treating contrast-induced nephropathy
#162Therapeutic agents comprising fusions of insulin and elastic peptides
#163Long-acting formulations of insulin
#164Mucosal delivery of drugs
#165FORMULATIONS OF ACTIVE AGENTS FOR SUSTAINED RELEASE
#166Vasoactive intestinal peptide release from microparticles
#167Methods for promoting neuronal outgrowth by insulin-like growth factor binding protein-like 1 (IGFBPL-1) in glaucoma or leber's optic neuropathy
#168Polymer-based sustained release device
#169Use of PACAP for the treatment of viral infections in aquatic organisms
#170Treatment of kidney fibrosis with VIP fragments
#171Methods for diagnosing, treating, and monitoring chronic inflammatory response syndrome
#172METHODS FOR TREATING ORGANS
#173NOVEL FORMULATIONS AND METHODS
#174Antagonism of the VIP signaling pathway
#175Combination therapy
#176VIP fragments and methods of use
#177Method of lowering cholesterol and triglycerides by administering exendins
#178Anti-diabetic compounds
#179Polymer-based sustained release device
#180Highly active polypeptides and methods of making and using the same
#181Devices, formulations, and methods for delivery of multiple beneficial agents
#182Therapeutic agents comprising insulin and elastin-like peptides
#183Glucagon analogues
#184Methods of treating diabetes using therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptides
#185Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use
#186METHODS FOR TREATING PULMONARY HYPERTENSION AND COMPOSITIONS COMPRISING VASOACTIVE INTESTINAL PEPTIDE
#187PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT OF DIABETES TYPE 2 PATIENTS
#188METHODS TO RESTORE GLYCEMIC CONTROL
#189THERAPEUTIC AGENTS COMPRISING ELASTIC PEPTIDES
#190GLP-1, exendin-4, peptide analogs and uses thereof
#191Pharmaceutical composition comprising a GLP-1 agonist and methionine
#192COACERVATION PROCESS
#193INSULIN PREPARATIONS CONTAINING METHIONINE
#194Pharmaceutical compositions for sustained release delivery of peptides
#195GLP-1 RECEPTOR AGONIST COMPOUNDS FOR SLEEP ENHANCEMENT
#196Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders
#197LONG-ACTING FORMULATIONS OF INSULINS
#198Endorphin Therapy Compositions and Methods of Use Thereof
#199Method for treating hyperglycemia with GLP-1
#200Mounting arrangement and coupling assembly for a drug-delivery device
#201MODIFICATION OF FEEDING BEHAVIOUR
#202Methods for the treatment of aortic fibrosis with VIP fragments
#203GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction
#204LONG-ACTING FORMULATIONS OF INSULINS
#205PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF
#206EXENDINS TO LOWER CHOLESTEROL AND TRIGLYCERIDES
#207Treatment of kidney disorders with VIP fragments
#208Corneal Neuritogenesis Promoter Containing Pacap and Its Derivative
#209Sustained release formulations using non-aqueous carriers
#210NOVEL SCREENS TO IDENTIFY AGENTS THAT MODULATE RETINAL BLOOD VESSEL FUNCTION AND PERICYTE FUNCTION AND DIAGNOSTIC AND THERAPEUTIC APPLICATION THEREFOR
#211Modified vasoactive intestinal peptides
#212Treatment of cardiac arrhythmias
#213Method of treating HIV in drug resistant non plasma viral reservoirs with monomeric DAPTA
#214Materials and Methods for Making Improved Micelle Compositions
#215TRANSDERMAL SYSTEM FOR EXTENDED DELIVERY OF INCRETINS AND INCRETN MIMETIC PEPTIDES
#216Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
#217METHOD OF TREATMENT OF DIABETES TYPE 2 COMPRISING ADD-ON THERAPY TO METFORMIN
#218Controlled release multidrug formulations for spinal cord injury
#219GLP-1 Receptor Agonists And Related Active Pharmaceutical Ingredients For Treatment Of Cancer
#220Methods and compositions for oral administration of proteins
#221Microparticle and pharmaceutical composition thereof
#222METHODS FOR TREATING OBESITY AND OBESITY RELATED DISEASES AND DISORDERS
#223Regulation of food preference using GLP-1 agonists
#224USE OF A PEPTIDE AS A THERAPEUTIC AGENT
#225Method of ameliorating symptoms of type 1-diabetes using GABA related compounds and GLP-1/exendin-4 compounds
#226Polymer-based sustained release device
#227Polymer-based sustained release device
#228Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
#229Composition and microsphere for controlled-release of exendin, and method preparing the same
#230INHIBITION OF PACAP SIGNALLING FOR THE PREVENTION AND TREATMENT OF THROMBOCYTOPENIA
#231Pharmaceutical Compositions of Hglp-1, Exendin-4 and Analogs Thereof
#232Reversible pegylated drugs
#233Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
#234BIOACTIVE SUBSTANCE-BLOOD PROTEIN CONJUGATE AND STABILIZATION OF A BIOACTIVE SUBSTANCE USING THE SAME
#235Methods for treating pulmonary hypertension and compositions comprising vasoactive intestinal peptide
#236Selective VPAC2 receptor peptide agonists
#237Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
#238TRANSMUCOSAL DELIVERY OF PEPTIDES AND PROTEINS
#239Microencapsulation and sustained release of biologically active polypeptides
#240GLP-1, exendin-4, peptide analogs and uses thereof
#241POLYMER-BASED SUSTAINED RELEASE DEVICE
#242DELIVERY SCAFFOLDS AND RELATED METHODS OF USE
#243Compounds and methods for increasing neurogenesis
#244Use of Exendins and GLP-1 Receptor Agonists for Altering Lipoprotein Particle Size and Subclass Composition
#245Methods to restore glycemic control
#246Devices, formulations, and methods for delivery of multiple beneficial agents
#247FIBRIN GLUE COMPOSITION FOR REPAIRING NERVE DAMAGE AND METHODS THEREOF
#248Chronic treatment regimen using glucagon-like insulinotropic peptides
#249Methods for treating obesity and obesity related diseases and disorders
#250Use of exendin and analogs thereof to delay or prevent cardiac remodeling
#251NOVEL SCREENS TO IDENTIFY AGENTS THAT MODULATE RETINAL BLOOD VESSEL FUNCTION AND PERICYTE FUNCTION AND DIAGNOSTIC AND THERAPEUTIC APPLICATION THEREFOR
#252GLP-1 AND METHODS FOR TREATING DIABETES
#253Transmucosal delivery of peptides and proteins
#254Methods of treatment using exendin peptides or GLP-1 peptides
#255Antisense Modulation of PTP1B Expression
#256Poly(lactide-co-glycolide) based sustained release microcapsules comprising a polypeptide and a sugar
#257Methods and compositions for treating ocular disorders
#258VIP fragments and methods of use
#259Mucosal Delivery of Stabilized Formulations of Exendin
#260PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION
#261Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis
#262Methods and Compositions Involving A1c Subunit of L-Type Calcium Channels in Smooth Muscle Cells
#263Combination of nateglinide or repaglinide with at least one further antidiabetic compound
#264Polymer-based sustained release device
#265Selective VPAC2 receptor peptide agonists
#266Coacervation Process
#267Methods of treating obesity with two different anti-obesity agents
#268Formulation for aviptadil
#269Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus
#270Polymer-based sustained release device
#271Polymer-based sustained release device
#272Polymer-based sustained release device
#273Polymer-based sustained release device
#274Compositions and methods for treatment of cardiovascular disease
#275Fibrin glue composition for repairing nerve damage and methods thereof
#276METHODS AND COMPOSITIONS FOR TREATING ERECTILE DYSFUNCTION
#277Pharmaceutical compositions for sustained release delivery of peptides
#278METHODS AND COMPOSITIONS FOR TREATING ERECTILE DYSFUNCTION
#279Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders
#280TREATMENT OF A WOUND WITH A VASODILATOR
#281Therapeutic compositions of oncomodulin
#282Polymer-based sustained release device
#283Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo
#284Peptide pharmaceutical compositions
#285Regulation of food preference using GLP-1 agonists
#286Methods and compositions for treating polycystic ovary syndrome
#287Methods for treating diabetes and related disorders using pde10a inhibitors
#288Microencapsulation and sustained release of biologically active polypeptides
#289Use of hydroxylated amino acids for treating diabetes
#290Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis
#291Method for screening substances capable of inhibiting the hyperplasia of pancreatic cells and/or the hypersecretion of insulin by pancreatic cells
#292Compositions and regime/regimen for treating the adverse signs of cutaneous skin aging
#293Stabilized, solid-state polypeptide particles
#294Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
#295Combination treatment using exendins and thiazolidinediones
#296Methods and compositions for enhanced transmucosal delivery of peptides and proteins
#297Reversible pegylated drugs
#298Pharmaceutical compositions and methods for restoring β-cell mass and function
#299Method for screening substances capable of inhibiting the hyperplasia of pancreatic cells and/or the hypersecretion of insulin by pancreatic cells
#300Polymer-based sustained release device